{"result": {"id": "c5ce3a16-8527-42c3-8604-6eec95538227", "choices": [{"finish_reason": "stop", "index": 0, "logprobs": null, "message": {"content": "(\"entity\"<|>CCB<|>ORGANIZATION<|>Calcium Channel Blocker (Dihydropyridine class) used for controlling hypertension, especially in patients with a history of myocardial infarction)\n##\n(\"entity\"<|>ACEI<|>ORGANIZATION<|>Angiotensin-Converting Enzyme Inhibitor used for hypertension management)\n##\n(\"entity\"<|>ARB<|>ORGANIZATION<|>Angiotensin II Receptor Blocker used for hypertension management)\n##\n(\"entity\"<|>SPIRONOLACTONE<|>ORGANIZATION<|>Diuretic used in specific cases of hypertension, particularly when estimated glomerular filtration rate is below 30ml·min-1·(1.73m2)-1)\n##\n(\"entity\"<|>LOOP DIURETIC<|>ORGANIZATION<|>Diuretic used when estimated glomerular filtration rate is below 30ml·min-1·(1.73m2)-1)\n##\n(\"entity\"<|>HYPERTENSION<|>EVENT<|>A medical condition characterized by high blood pressure, often requiring multiple medications and lifestyle changes for management)\n##\n(\"entity\"<|>DIABETES<|>EVENT<|>A chronic condition often associated with hypertension, requiring careful management of blood pressure)\n##\n(\"entity\"<|>DYSLIPIDEMIA<|>EVENT<|>A condition often associated with hypertension, requiring management of lipid levels)\n##\n(\"relationship\"<|>CCB<|>HYPERTENSION<|>CCB is used to control hypertension, especially in patients with a history of myocardial infarction<|>8)\n##\n(\"relationship\"<|>ACEI<|>HYPERTENSION<|>ACEI is used to manage hypertension<|>8)\n##\n(\"relationship\"<|>ARB<|>HYPERTENSION<|>ARB is used to manage hypertension<|>8)\n##\n(\"relationship\"<|>SPIRONOLACTONE<|>HYPERTENSION<|>Spironolactone is used in specific cases of hypertension<|>6)\n##\n(\"relationship\"<|>LOOP DIURETIC<|>HYPERTENSION<|>Loop diuretics are used in specific cases of hypertension<|>6)\n##\n(\"relationship\"<|>HYPERTENSION<|>DIABETES<|>Hypertension is often associated with diabetes, requiring careful management<|>7)\n##\n(\"relationship\"<|>HYPERTENSION<|>DYSLIPIDEMIA<|>Hypertension is often associated with dyslipidemia, requiring management of lipid levels<|>7)\n<|COMPLETE|>", "refusal": null, "role": "assistant", "annotations": null, "audio": null, "function_call": null, "tool_calls": null}}], "created": 1752166340, "model": "deepseek-chat", "object": "chat.completion", "service_tier": null, "system_fingerprint": "fp_8802369eaa_prod0623_fp8_kvcache", "usage": {"completion_tokens": 586, "prompt_tokens": 2462, "total_tokens": 3048, "completion_tokens_details": null, "prompt_tokens_details": {"audio_tokens": null, "cached_tokens": 1792}, "prompt_cache_hit_tokens": 1792, "prompt_cache_miss_tokens": 670}}, "input": {"messages": [{"content": "\n-Goal-\nGiven a text document that is potentially relevant to this activity and a list of entity types, identify all entities of those types from the text and all relationships among the identified entities.\n \n-Steps-\n1. Identify all entities. For each identified entity, extract the following information:\n- entity_name: Name of the entity, capitalized\n- entity_type: One of the following types: [organization,person,geo,event]\n- entity_description: Comprehensive description of the entity's attributes and activities\nFormat each entity as (\"entity\"<|><entity_name><|><entity_type><|><entity_description>)\n \n2. From the entities identified in step 1, identify all pairs of (source_entity, target_entity) that are *clearly related* to each other.\nFor each pair of related entities, extract the following information:\n- source_entity: name of the source entity, as identified in step 1\n- target_entity: name of the target entity, as identified in step 1\n- relationship_description: explanation as to why you think the source entity and the target entity are related to each other\n- relationship_strength: a numeric score indicating strength of the relationship between the source entity and target entity\n Format each relationship as (\"relationship\"<|><source_entity><|><target_entity><|><relationship_description><|><relationship_strength>)\n \n3. Return output in English as a single list of all the entities and relationships identified in steps 1 and 2. Use **##** as the list delimiter.\n \n4. When finished, output <|COMPLETE|>\n \n######################\n-Examples-\n######################\nExample 1:\nEntity_types: ORGANIZATION,PERSON\nText:\nThe Verdantis's Central Institution is scheduled to meet on Monday and Thursday, with the institution planning to release its latest policy decision on Thursday at 1:30 p.m. PDT, followed by a press conference where Central Institution Chair Martin Smith will take questions. Investors expect the Market Strategy Committee to hold its benchmark interest rate steady in a range of 3.5%-3.75%.\n######################\nOutput:\n(\"entity\"<|>CENTRAL INSTITUTION<|>ORGANIZATION<|>The Central Institution is the Federal Reserve of Verdantis, which is setting interest rates on Monday and Thursday)\n##\n(\"entity\"<|>MARTIN SMITH<|>PERSON<|>Martin Smith is the chair of the Central Institution)\n##\n(\"entity\"<|>MARKET STRATEGY COMMITTEE<|>ORGANIZATION<|>The Central Institution committee makes key decisions about interest rates and the growth of Verdantis's money supply)\n##\n(\"relationship\"<|>MARTIN SMITH<|>CENTRAL INSTITUTION<|>Martin Smith is the Chair of the Central Institution and will answer questions at a press conference<|>9)\n<|COMPLETE|>\n\n######################\nExample 2:\nEntity_types: ORGANIZATION\nText:\nTechGlobal's (TG) stock skyrocketed in its opening day on the Global Exchange Thursday. But IPO experts warn that the semiconductor corporation's debut on the public markets isn't indicative of how other newly listed companies may perform.\n\nTechGlobal, a formerly public company, was taken private by Vision Holdings in 2014. The well-established chip designer says it powers 85% of premium smartphones.\n######################\nOutput:\n(\"entity\"<|>TECHGLOBAL<|>ORGANIZATION<|>TechGlobal is a stock now listed on the Global Exchange which powers 85% of premium smartphones)\n##\n(\"entity\"<|>VISION HOLDINGS<|>ORGANIZATION<|>Vision Holdings is a firm that previously owned TechGlobal)\n##\n(\"relationship\"<|>TECHGLOBAL<|>VISION HOLDINGS<|>Vision Holdings formerly owned TechGlobal from 2014 until present<|>5)\n<|COMPLETE|>\n\n######################\nExample 3:\nEntity_types: ORGANIZATION,GEO,PERSON\nText:\nFive Aurelians jailed for 8 years in Firuzabad and widely regarded as hostages are on their way home to Aurelia.\n\nThe swap orchestrated by Quintara was finalized when $8bn of Firuzi funds were transferred to financial institutions in Krohaara, the capital of Quintara.\n\nThe exchange initiated in Firuzabad's capital, Tiruzia, led to the four men and one woman, who are also Firuzi nationals, boarding a chartered flight to Krohaara.\n\nThey were welcomed by senior Aurelian officials and are now on their way to Aurelia's capital, Cashion.\n\nThe Aurelians include 39-year-old businessman Samuel Namara, who has been held in Tiruzia's Alhamia Prison, as well as journalist Durke Bataglani, 59, and environmentalist Meggie Tazbah, 53, who also holds Bratinas nationality.\n######################\nOutput:\n(\"entity\"<|>FIRUZABAD<|>GEO<|>Firuzabad held Aurelians as hostages)\n##\n(\"entity\"<|>AURELIA<|>GEO<|>Country seeking to release hostages)\n##\n(\"entity\"<|>QUINTARA<|>GEO<|>Country that negotiated a swap of money in exchange for hostages)\n##\n##\n(\"entity\"<|>TIRUZIA<|>GEO<|>Capital of Firuzabad where the Aurelians were being held)\n##\n(\"entity\"<|>KROHAARA<|>GEO<|>Capital city in Quintara)\n##\n(\"entity\"<|>CASHION<|>GEO<|>Capital city in Aurelia)\n##\n(\"entity\"<|>SAMUEL NAMARA<|>PERSON<|>Aurelian who spent time in Tiruzia's Alhamia Prison)\n##\n(\"entity\"<|>ALHAMIA PRISON<|>GEO<|>Prison in Tiruzia)\n##\n(\"entity\"<|>DURKE BATAGLANI<|>PERSON<|>Aurelian journalist who was held hostage)\n##\n(\"entity\"<|>MEGGIE TAZBAH<|>PERSON<|>Bratinas national and environmentalist who was held hostage)\n##\n(\"relationship\"<|>FIRUZABAD<|>AURELIA<|>Firuzabad negotiated a hostage exchange with Aurelia<|>2)\n##\n(\"relationship\"<|>QUINTARA<|>AURELIA<|>Quintara brokered the hostage exchange between Firuzabad and Aurelia<|>2)\n##\n(\"relationship\"<|>QUINTARA<|>FIRUZABAD<|>Quintara brokered the hostage exchange between Firuzabad and Aurelia<|>2)\n##\n(\"relationship\"<|>SAMUEL NAMARA<|>ALHAMIA PRISON<|>Samuel Namara was a prisoner at Alhamia prison<|>8)\n##\n(\"relationship\"<|>SAMUEL NAMARA<|>MEGGIE TAZBAH<|>Samuel Namara and Meggie Tazbah were exchanged in the same hostage release<|>2)\n##\n(\"relationship\"<|>SAMUEL NAMARA<|>DURKE BATAGLANI<|>Samuel Namara and Durke Bataglani were exchanged in the same hostage release<|>2)\n##\n(\"relationship\"<|>MEGGIE TAZBAH<|>DURKE BATAGLANI<|>Meggie Tazbah and Durke Bataglani were exchanged in the same hostage release<|>2)\n##\n(\"relationship\"<|>SAMUEL NAMARA<|>FIRUZABAD<|>Samuel Namara was a hostage in Firuzabad<|>2)\n##\n(\"relationship\"<|>MEGGIE TAZBAH<|>FIRUZABAD<|>Meggie Tazbah was a hostage in Firuzabad<|>2)\n##\n(\"relationship\"<|>DURKE BATAGLANI<|>FIRUZABAD<|>Durke Bataglani was a hostage in Firuzabad<|>2)\n<|COMPLETE|>\n\n######################\n-Real Data-\n######################\nEntity_types: organization,person,geo,event\nText: e\t\n老年\t+\t+\t+\t\t±\n糖尿病\t±\t+\t+\t±\t\n血脂异常\t±\t+\t+\t\t\n　　注 ：CCB 钙通道阻滞剂(二氢吡啶类);ACEI 血管紧张素转换 酶抑制剂；ARB 血管紧张素Ⅱ受体阻滞剂；+适用；-证据不足或不 适用；±可能适用；“对伴心肌梗死病史者可用长效CCB控制高血 压；氨氯地平和非洛地平可用；冠心病二级预防；螺内酯；估算 的肾小球滤过率<30ml·min-1·(1.73m2)-1  时应选用襻利尿剂\n\n\n\n　\n( 2 ) 高 血 压 合 并 卒 中 ：\n\n\n\n\n\n\n\n\n\n\n(7)难治性高血压：\n\n\n\n\n\n　\n(4)高血压合并心力衰竭：\n\n　\n(5)高血压合并肾脏疾病：\n　\n\n\n　　①定义：在改善生活方式基础上应用可耐受的 足够剂量且合理的3种降压药物(包括一种噻嗪类 利尿剂)至少治疗4周后，诊室和诊室外(包括 ABPM或 HBPM)血压值仍在目标水平之上，或至少 需4种药物才能使血压达标，称难治性高血压。\n　　确定患者是否属于难治性高血压常需配合采 用诊室外血压测量(ABPM或 HBPM), 以排除白大 衣血压效应以及假性高血压。\n　　②寻找影响血压控制不良的原因和并存的疾  病因素↓:较常见的原因是患者治疗依从性差(未  坚持服药);降压药物选择使用不当(药物组合不合  理、使用药物剂量不足);应用了拮抗降压疗效的药  物，包括口服避孕药、环孢素、促红细胞生成素、糖  皮质激素、非甾体类抗炎药、抗抑郁药，可卡因及某  些中药(如甘草、麻黄)等；其他影响因素，如不良生  活方式、肥胖、容量负荷过重(利尿剂治疗不充分、 高盐摄入、进展性肾功能不全);或某些并存疾病状  况，如糖尿病、血脂异常、慢性疼痛以及长期失眠、 焦虑/抑郁等。患者可能存在一种以上可纠正或难  以纠正的原因。排除上述因素后，应警惕继发性高\n\n(6)高血压合并糖尿病：                        血 压 的 可 能 ， 启 动 继 发 性 高 血 压 筛 查 。\n\n\n\n③处理原则24-261:\n　　@经初步筛查并去除病因，仍不能有效控制血 压的患者 ， 应转诊 。\n　　⑥提倡诊室外血压测量(ABPM及HBPM), 与 患者有效沟通。关注患者长期用药依从性。\n　　C 尽量消除影响因素。主要有肥胖、代谢紊 乱 、 钠盐摄入过多等 。\n①调整降压联合方案。\n(三)高血压患者治疗流程\n　　1.无合并症高血压患者的治疗流程：\n######################\nOutput:", "role": "user"}], "parameters": {"model": "deepseek-chat", "frequency_penalty": 0.0, "max_tokens": null, "n": 1, "presence_penalty": 0.0, "temperature": 0.0, "top_p": 1.0}}, "key": "chat_2bfc95c9dc96e74c440227f1c5e491968a26893ec2da0cdd384569d2898c3ca3_v2"}